Similar outcome of calreticulin type I and calreticulin type II mutations following RIC allogeneic haematopoietic stem cell transplantation for myelofibrosis

[1] Rumi E(2014)Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis Blood 124 1062-1069

[2] Pietra D(2014)CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons Leukemia 28 1472-1477

[3] Pascutto C(2014)Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact Leukemia 28 1568-1570

[4] Guglielmelli P(2013)Somatic mutations of calreticulin in myeloproliferative neoplasms N Engl J Med 369 2379-2390

[5] Martinez-Trillos A(2013)Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2 N Engl J Med 369 2391-2405

[6] Casetti I(2014)The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants Blood 124 2465-2466

[7] Tefferi A(2015)Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis Blood Cancer J 5 e360-1555

[8] Lasho TL(2014)Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation Leukemia 28 1552-873

[9] Finke CM(2016)Digital-PCR assay for screening and quantitative monitoring of calreticulin (CALR) type-2 positive patients with myelofibrosis following allogeneic stem cell transplantation Bone Marrow Transplantation 51 872-1708

[10] Knudson RA(2010)A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) Blood 115 1703-397

[1] Rumi E(2014)Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis Blood 124 1062-1069

[2] Pietra D(2014)CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons Leukemia 28 1472-1477

[3] Pascutto C(2014)Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact Leukemia 28 1568-1570

[4] Guglielmelli P(2013)Somatic mutations of calreticulin in myeloproliferative neoplasms N Engl J Med 369 2379-2390

[5] Martinez-Trillos A(2013)Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2 N Engl J Med 369 2391-2405

[6] Casetti I(2014)The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants Blood 124 2465-2466

[7] Tefferi A(2015)Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis Blood Cancer J 5 e360-1555

[8] Lasho TL(2014)Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation Leukemia 28 1552-873

[9] Finke CM(2016)Digital-PCR assay for screening and quantitative monitoring of calreticulin (CALR) type-2 positive patients with myelofibrosis following allogeneic stem cell transplantation Bone Marrow Transplantation 51 872-1708

[10] Knudson RA(2010)A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) Blood 115 1703-397